Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: pasireotide Clear all

Conditions: Cushing Disease
Interventions: Pasireotide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 3
States / cities: Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania

Conditions: Neuroendocrine Tumors
Interventions: Pasireotide, Sir-sphere Radioembolization, Everolimus; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: docetaxel, pasireotide, prednisone; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast
Interventions: SOM 230 / Pasireotide; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Polycystic Liver Disease
Interventions: Pasireotide LAR, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pancreatic Cancer
Interventions: SOM 230 LAR, Gemcitabine; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Multiple Myeloma
Interventions: Pasireotide, Everolimus; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Gonadotroph Adenomas
Interventions: pasireotide LAR; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cushing's Disease, Acromegaly
Interventions: Pasireotide s.c., Sitagliptin, Liraglutide, Insulin, Pasireotide LAR, Metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 15
States / cities: Multiple Locations, California • Torrance, California • Ventura, California + 10 more

Conditions: Acromegaly
Interventions: Pasireotide long acting release formulation; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 37
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 30 more

Conditions: Small Cell Lung Cancer
Interventions: Topotecan and Pasireotide; Drug
Lead sponsor: South Florida Veterans Affairs Foundation for Research and Education; Federal
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cushings Disease
Interventions: Pasireotide with or without cabergoline; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • Portland, Oregon

Conditions: Carcinoid Tumors
Interventions: Pasireotide (SOM230); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 4
States / cities: Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more

Conditions: Acromegaly
Interventions: Pasireotide (SOM230), Octreotide (Sandostatin); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Neuroendocrine Tumors, Carcinoid Tumors
Interventions: Pasireotide Long Acting Release (LAR); Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 2
States / cities: Stanford, California • Tampa, Florida

Conditions: Cushing's Disease
Interventions: pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Torrance, California + 9 more

Conditions: Uveal Melanoma
Interventions: RAD001 (Everolimus) and Pasireotide (SOM230) LAR; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Acromegaly
Interventions: Pasireotide, Octreotide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 14
States / cities: Los Angeles, California • Stanford, California • Gainesville, Florida + 9 more

Conditions: Cushings Disease
Interventions: Pasireotide; Drug
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more

Conditions: Pituitary Tumor, ACTH-producing Pituitary Tumour
Interventions: Pasireotide LAR; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
Interventions: Pasireotide, Everolimus, Laboratory biomarker analysis; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: New Haven, Connecticut • Philadelphia, Pennsylvania

Conditions: Acromegaly
Interventions: Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Cushing's Syndrome
Interventions: SOM230 s.c.; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Portland, Oregon + 2 more

Conditions: Hyperglycemia
Interventions: pasireotide; Drug
Lead sponsor: Robert R. Henry, MD; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

Pasireotide LAR in Severe Polycystic Liver Disease

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly

Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers